GOLDMAN SACHS GROUP INC - AVALO THERAPEUTICS INC ownership

AVALO THERAPEUTICS INC's ticker is and the CUSIP is 05338F207. A total of 27 filers reported holding AVALO THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
GOLDMAN SACHS GROUP INC ownership history of AVALO THERAPEUTICS INC
ValueSharesWeighting
Q1 2023$56,457
-66.2%
32,261
-2.6%
0.00%
Q4 2022$166,868
+141313.6%
33,108
-7.1%
0.00%
Q3 2022$11835,6440.00%
Other shareholders
AVALO THERAPEUTICS INC shareholders Q2 2023
NameSharesValueWeighting ↓
VR Adviser, LLC 1,000,000$1,750,0000.34%
GREAT POINT PARTNERS LLC 474,639$830,6180.16%
ARMISTICE CAPITAL, LLC 4,415,000$7,726,2500.11%
Nantahala Capital Management 808,844$1,415,4770.11%
Monashee Investment Management LLC 60,000$105,0000.03%
BRAIDWELL LP 247,254$432,6950.01%
Point72 Asset Management, L.P. 1,100,737$1,926,2900.01%
Alyeska Investment Group, L.P. 400,000$700,0000.01%
Maven Securities LTD 92,937$162,6400.00%
TCI Wealth Advisors, Inc. 251$4400.00%
View complete list of AVALO THERAPEUTICS INC shareholders